Report Detail
Global Recombinant Plasma Proteins Market Growth (Status and Outlook) 2019-2024
- RnM3190831 |
- 26 March, 2019 |
- Global |
- 115 Pages |
- LPI(LP Information) |
- Other
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
According to this study, over the next five years the Recombinant Plasma Proteins market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Recombinant Plasma Proteins business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Recombinant Plasma Proteins market by product type, application, key companies and key regions.
This study considers the Recombinant Plasma Proteins value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Recombinant Plasma Proteins market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Recombinant Plasma Proteins market by identifying its various subsegments.
Focuses on the key global Recombinant Plasma Proteins players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Recombinant Plasma Proteins with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Recombinant Plasma Proteins submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Recombinant Plasma Proteins Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Recombinant Plasma Proteins Market Size 2014-2024
- 2.1.2 Recombinant Plasma Proteins Market Size CAGR by Region
- 2.2 Recombinant Plasma Proteins Segment by Type
- 2.2.1 Chinese Hamster Ovary (CHO) Cell Line
- 2.2.2 Baby Hamster Kidney (BHK) Cell Line
- 2.2.3 Human Embryonic Kidney (HEK) Cell Line
- 2.2.4 Others
- 2.3 Recombinant Plasma Proteins Market Size by Type
- 2.3.1 Global Recombinant Plasma Proteins Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Recombinant Plasma Proteins Market Size Growth Rate by Type (2014-2019)
- 2.4 Recombinant Plasma Proteins Segment by Application
- 2.4.1 Hemophilia A
- 2.4.2 Hemophilia B
- 2.4.3 Von Willebrand Disease
- 2.4.4 Others
- 2.5 Recombinant Plasma Proteins Market Size by Application
- 2.5.1 Global Recombinant Plasma Proteins Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Recombinant Plasma Proteins Market Size Growth Rate by Application (2014-2019)
3 Global Recombinant Plasma Proteins by Players
- 3.1 Global Recombinant Plasma Proteins Market Size Market Share by Players
- 3.1.1 Global Recombinant Plasma Proteins Market Size by Players (2017-2019)
- 3.1.2 Global Recombinant Plasma Proteins Market Size Market Share by Players (2017-2019)
- 3.2 Global Recombinant Plasma Proteins Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Recombinant Plasma Proteins by Regions
- 4.1 Recombinant Plasma Proteins Market Size by Regions
- 4.2 Americas Recombinant Plasma Proteins Market Size Growth
- 4.3 APAC Recombinant Plasma Proteins Market Size Growth
- 4.4 Europe Recombinant Plasma Proteins Market Size Growth
- 4.5 Middle East & Africa Recombinant Plasma Proteins Market Size Growth
5 Americas
- 5.1 Americas Recombinant Plasma Proteins Market Size by Countries
- 5.2 Americas Recombinant Plasma Proteins Market Size by Type
- 5.3 Americas Recombinant Plasma Proteins Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Recombinant Plasma Proteins Market Size by Countries
- 6.2 APAC Recombinant Plasma Proteins Market Size by Type
- 6.3 APAC Recombinant Plasma Proteins Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Recombinant Plasma Proteins by Countries
- 7.2 Europe Recombinant Plasma Proteins Market Size by Type
- 7.3 Europe Recombinant Plasma Proteins Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Recombinant Plasma Proteins by Countries
- 8.2 Middle East & Africa Recombinant Plasma Proteins Market Size by Type
- 8.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Recombinant Plasma Proteins Market Forecast
- 10.1 Global Recombinant Plasma Proteins Market Size Forecast (2019-2024)
- 10.2 Global Recombinant Plasma Proteins Forecast by Regions
- 10.2.1 Global Recombinant Plasma Proteins Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Recombinant Plasma Proteins Forecast by Type
- 10.8 Global Recombinant Plasma Proteins Forecast by Application
11 Key Players Analysis
- 11.1 CSL Limited
- 11.1.1 Company Details
- 11.1.2 Recombinant Plasma Proteins Product Offered
- 11.1.3 CSL Limited Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 CSL Limited News
- 11.2 Shire (Takeda Pharmaceutical Company Limited)
- 11.2.1 Company Details
- 11.2.2 Recombinant Plasma Proteins Product Offered
- 11.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Shire (Takeda Pharmaceutical Company Limited) News
- 11.3 Octapharma
- 11.3.1 Company Details
- 11.3.2 Recombinant Plasma Proteins Product Offered
- 11.3.3 Octapharma Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Octapharma News
- 11.4 Novo Nordisk
- 11.4.1 Company Details
- 11.4.2 Recombinant Plasma Proteins Product Offered
- 11.4.3 Novo Nordisk Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Novo Nordisk News
- 11.5 Bayer
- 11.5.1 Company Details
- 11.5.2 Recombinant Plasma Proteins Product Offered
- 11.5.3 Bayer Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Bayer News
- 11.6 Bioverativ Therapeutics, Inc. (Sanofi)
- 11.6.1 Company Details
- 11.6.2 Recombinant Plasma Proteins Product Offered
- 11.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Bioverativ Therapeutics, Inc. (Sanofi) News
- 11.7 Aptevo Therapeutics
- 11.7.1 Company Details
- 11.7.2 Recombinant Plasma Proteins Product Offered
- 11.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Aptevo Therapeutics News
- 11.8 Pharming Group
- 11.8.1 Company Details
- 11.8.2 Recombinant Plasma Proteins Product Offered
- 11.8.3 Pharming Group Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Pharming Group News
- 11.9 Pfizer
- 11.9.1 Company Details
- 11.9.2 Recombinant Plasma Proteins Product Offered
- 11.9.3 Pfizer Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2019)
- 11.9.4 Main Business Overview
- 11.9.5 Pfizer News
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Recombinant Plasma Proteins . Industry analysis & Market Report on Recombinant Plasma Proteins is a syndicated market report, published as Global Recombinant Plasma Proteins Market Growth (Status and Outlook) 2019-2024. It is complete Research Study and Industry Analysis of Recombinant Plasma Proteins market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
